Login to Your Account

Novartis Passes on Idenix Lead HCV Antiviral Drug

By Catherine Hollingsworth

Monday, November 2, 2009
Idenix Pharmaceuticals Inc. is looking to partner its early stage compound for hepatic C virus (HCV), now that Swiss drugmaker Novartis Pharma AG has taken a pass on it. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription